Business Description
Tibet Rhodiola Pharmaceutical Holding Co
ISIN : CNE000000ZW7
Share Class Description:
SHSE:600211: Class ATotal Employee Number:
671Compare
Compare
Traded in other countries / regions
600211.China Index Membership
SSE Composite Index IPO Date
1999-07-21Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.6 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 0.98 | |||||
Interest Coverage | 41.5 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.63 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.3 | |||||
3-Year EBITDA Growth Rate | 27.5 | |||||
3-Year EPS without NRI Growth Rate | 33.1 | |||||
3-Year FCF Growth Rate | 10.4 | |||||
3-Year Book Growth Rate | 8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.11 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.26 | |||||
9-Day RSI | 58.32 | |||||
14-Day RSI | 54.59 | |||||
3-1 Month Momentum % | -11.1 | |||||
6-1 Month Momentum % | -19.05 | |||||
12-1 Month Momentum % | -1.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 2.77 | |||||
Cash Ratio | 2.3 | |||||
Days Inventory | 331.64 | |||||
Days Sales Outstanding | 66.68 | |||||
Days Payable | 58.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.53 | |||||
Dividend Payout Ratio | 0.53 | |||||
3-Year Dividend Growth Rate | 93.1 | |||||
Forward Dividend Yield % | 9.04 | |||||
5-Year Yield-on-Cost % | 23.65 | |||||
Shareholder Yield % | 1.66 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.77 | |||||
Operating Margin % | 34.07 | |||||
Net Margin % | 32.32 | |||||
EBITDA Margin % | 36.09 | |||||
FCF Margin % | 35.55 | |||||
OCF Margin % | 36.03 | |||||
ROE % | 24.79 | |||||
ROA % | 16.47 | |||||
ROIC % | 38.88 | |||||
3-Year ROIIC % | 44.33 | |||||
ROC (Joel Greenblatt) % | 132.92 | |||||
ROCE % | 24.33 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.12 | |||||
Forward PE Ratio | 12.7 | |||||
PE Ratio without NRI | 13.08 | |||||
Shiller PE Ratio | 23.42 | |||||
Price-to-Owner-Earnings | 14.1 | |||||
PEG Ratio | 0.51 | |||||
PS Ratio | 4.23 | |||||
PB Ratio | 3.25 | |||||
Price-to-Tangible-Book | 3.59 | |||||
Price-to-Free-Cash-Flow | 11.9 | |||||
Price-to-Operating-Cash-Flow | 11.75 | |||||
EV-to-EBIT | 9.49 | |||||
EV-to-EBITDA | 9.49 | |||||
EV-to-Revenue | 3.42 | |||||
EV-to-FCF | 9.63 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 1.11 | |||||
Price-to-DCF (Earnings Based) | 0.42 | |||||
Price-to-DCF (FCF Based) | 0.72 | |||||
Price-to-Median-PS-Value | 0.81 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.52 | |||||
Price-to-Graham-Number | 1.44 | |||||
| Price-to-Net-Current-Asset-Value | 5.5 | |||||
| Price-to-Net-Cash | 9.52 | |||||
Earnings Yield (Greenblatt) % | 10.54 | |||||
FCF Yield % | 8.39 | |||||
Forward Rate of Return (Yacktman) % | 26.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tibet Rhodiola Pharmaceutical Holding Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,992.977 | ||
| EPS (TTM) (Â¥) | 3 | ||
| Beta | 1.1588 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.42 | ||
| Volatility % | 22.75 | ||
| 14-Day RSI | 54.59 | ||
| 14-Day ATR (Â¥) | 1.441172 | ||
| 20-Day SMA (Â¥) | 37.613 | ||
| 12-1 Month Momentum % | -1.77 | ||
| 52-Week Range (Â¥) | 34.8 - 57.98 | ||
| Shares Outstanding (Mil) | 322.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tibet Rhodiola Pharmaceutical Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tibet Rhodiola Pharmaceutical Holding Co Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.876000 Cash Dividend | 2026-05-22 | 41.10 (-0.19%) | ||
| CNY 0.881000 Cash Dividend | 2025-09-01 | 47.16 (-0.65%) | ||
| CNY 0.728000 Cash Dividend | 2025-04-22 | 37.36 (+1.36%) | ||
| CNY 0.262000 Cash Dividend | 2025-01-21 | 36.07 (-0.36%) | ||
| CNY 0.967000 Cash Dividend | 2024-08-29 | 35.25 (-0.56%) | ||
| 1.3:1 Stock Split | 2024-04-30 | 36.60 (+3.41%) | ||
| 1.4:1 Stock Split | 2020-04-17 | 21.16 (-1.93%) | ||
| 1.1:1 Stock Split | 2010-09-07 | 7.67 (-3.40%) | ||
| 1.358:1 Stock Split | 2007-09-10 | 9.65 (+0.00%) |
Show
Entries
Tibet Rhodiola Pharmaceutical Holding Co Frequently Asked Questions
What is Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)'s stock price today?
The current price of SHSE:600211 is ¥39.35. The 52 week high of SHSE:600211 is ¥57.98 and 52 week low is ¥34.80.
When is next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)?
The next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is .
Does Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) pay dividends? If so, how much?
The Dividend Yield %  of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 4.53% (As of Today), Highest Dividend Payout Ratio of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) was 1.89. The lowest was 0.17. And the median was 0.48. The  Forward Dividend Yield % of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 9.04%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Tibet Rhodiola Pharmaceutical Holding Co
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers